US · OFIX
Orthofix Medical Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Lewisville, TX 75056
- Website
- orthofix.com
Price · as of 2025-12-31
$11.91
Market cap 535.78M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $39.59 | +232.41% |
| Intrinsic Value(DCF) | $5.35 | -55.08% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $39.99 | $63.04 | $0.00 | $7.16 | $0.00 |
| 2012 | $38.34 | $393.42 | $2.20 | $30.62 | $0.00 |
| 2013 | $22.96 | $53.69 | $0.00 | $6.03 | $7.14 |
| 2014 | $32.80 | $83.29 | $0.00 | $11.02 | $0.00 |
| 2015 | $41.26 | $84.75 | $0.00 | $11.85 | $0.00 |
| 2016 | $34.93 | $84.89 | $0.00 | $12.41 | $1.92 |
| 2017 | $59.32 | $86.58 | $0.64 | $15.13 | $4.70 |
| 2018 | $54.99 | $92.53 | $0.12 | $17.95 | $9.21 |
| 2019 | $32.82 | $101.80 | $0.00 | $6.04 | $0.00 |
| 2020 | $46.76 | $66.60 | $0.00 | $14.81 | $0.00 |
| 2021 | $32.07 | $180.02 | $0.00 | $3.74 | $0.00 |
| 2022 | $17.64 | $164.34 | $0.00 | $8.30 | $0.00 |
| 2023 | $14.00 | $27.76 | $137.44 | $0.00 | $0.00 |
| 2024 | $17.16 | $82.05 | $80.77 | $0.00 | $0.00 |
| 2025 | $13.37 | $39.59 | $47.68 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Orthofix Medical Inc.'s (OFIX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $39.59
- Current price
- $11.91
- AI upside
- +232.41%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.35
-55.08% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| OFIX | Orthofix Medical Inc. | $11.91 | 535.78M | +232% | -55% | — | — | — | 1.18 | 0.65 | -30.45 | — | 2.92 | 67.09% | -8.33% | -11.21% | 0.00% | -11.44% | 0.00% | 0.51 | -3.92 | 2.45 | 1.28 | -6.59 | -3091.00% | 285.00% | -8592.00% | -0.24% | 0.20 | -0.21% | 0.00% | — | 0.00% | -9.94 | -532.03 | 0.83 | 1.24 |
| ABSI | Absci Corporation | $2.74 | 412.02M | +823% | -47% | — | +302% | -3.34 | 1.92 | 75.86 | -2.57 | — | 2.56 | -1277.57% | -2401.59% | -2274.06% | -58.04% | -127.20% | -47.86% | 0.06 | -192.72 | 4.67 | 3.92 | 0.33 | -2167.00% | -2071.00% | 1116.00% | -21.17% | -2.53 | -85.05% | 0.00% | 0.00% | 0.00% | -2.22 | -3.32 | 53.29 | 1.58 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| BFLY | Butterfly Network, Inc. | $3.79 | 957.36M | +668% | -29% | — | — | -12.35 | 4.85 | 9.75 | -12.15 | — | 5.05 | 46.85% | -88.53% | -78.95% | -42.25% | -104.05% | -27.89% | 0.09 | -58.00 | 3.83 | 2.72 | 1.97 | -882.00% | 1896.00% | -6386.00% | -1.69% | -0.20 | -19.32% | 0.00% | 0.00% | 7.02% | -9.47 | -51.01 | 8.39 | 1.64 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| ESPR | Esperion Therapeutics, In… | $3.35 | 661.73M | +1,302% | +27,124% | — | — | -6.11 | -0.81 | 0.95 | 100.78 | — | -0.81 | 79.36% | 16.37% | -15.57% | 12.27% | 177.11% | -18.83% | -1.52 | 0.92 | 1.37 | 0.91 | 58.98 | -8621.00% | 18566.00% | -8231.00% | -7.58% | -0.10 | -78.04% | 0.00% | 0.00% | 3.87% | 14.02 | -31.82 | 2.30 | -4.45 |
| LAB | Standard BioTools Inc. | $1.13 | 434.56M | +2,535% | -50% | -88% | +606% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
| PACB | Pacific Biosciences of Ca… | $1.68 | 507.2M | +1,311% | -61% | — | — | -0.89 | 90.85 | 3.04 | -28.24 | -1.27 | -1.48 | 31.67% | -348.46% | -341.47% | -213.45% | -87.50% | -53.45% | 141.98 | -80.18 | 6.89 | 5.79 | -14.03 | 7009.00% | 389.00% | -4633.00% | -23.44% | -2.04 | -17.88% | 0.00% | 0.00% | 28.22% | -1.73 | -8.48 | 6.04 | -1.28 |
| SIBN | SI-BONE, Inc. | $15.52 | 673.43M | +222% | +44% | -88% | — | -36.13 | 3.85 | 3.40 | -49.18 | — | 3.85 | 79.57% | -11.11% | -9.41% | -10.97% | -52.40% | -8.06% | 0.01 | -4.23 | 8.55 | 7.03 | 3.77 | -4133.00% | 2019.00% | -6035.00% | -1.33% | -0.03 | -21.33% | 0.00% | 0.00% | 6.39% | -24.02 | -59.01 | 2.67 | 5.57 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Orthofix Medical Inc.
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions, as well as markets regenerative non-tissue biologic solutions derived from synthetic materials. The Global Orthopedics segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
- CEO
- Massimo Calafiore
- Employees
- 1.62K
- Beta
- 0.76
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.35 ÷ $11.91) − 1 = -55.08% (DCF, example).